RDD Pharma Announces Fecal Incontinence Patents Granted in EU, China & Russia

NEW YORK, Sept. 27, 2016 /PRNewswire/ -- RDD Pharma, a leader in developing treatments for anorectal disorders, announces that it has been granted patents in the EU, China, and Russia for methods for treating fecal incontinence. The patents are based on the increase in resting pressure via a topical administration of RDD 0315, an alpha-agonist.  Patents are also pending in U.S., Japan, Australia, Brazil, Canada, India and Israel.

RDD 0315 is currently being studied in the treatment of fecal incontinence associated with spinal cord injury (SCI). A successful placebo-controlled Phase 2a study was recently completed showing statistical significance and a ~25% reduction in unwanted fecal incontinence episodes in SCI patients. Good tolerability and safety was also observed, with no systemic absorption as indicated by plasma levels of RDD-0315 being below detectable limits.

About RDD Pharma

RDD is a privately held specialty pharma company, backed by Orbimed.  RDD focuses on fast-track development and commercialization of innovative therapeutics for anorectal diseases and gastrointestinal disorders.   The company has two clinical stage products which serve significant unmet needs: (1) RDD-1219 for chronic anal fissure, currently enrolling patients in a multicenter European Phase 3 study and (2) RDD-0315 for fecal incontinence, an indication for which there are no approved Rx products.

About Fecal Incontinence

Fecal incontinence results from damaged or weakened anal sphincter muscles. Treatment options are very limited.  It is a condition that can occur at any age and is often devastating to a person's quality of life.  For the elderly, fecal incontinence often results in early institutionalization because family members have difficulty coping with the problem at home.  Over 8% of non-institutionalized adults (~20 million) suffer from fecal incontinence in the US. Currently, there are no prescription Rx therapies available for treating fecal incontinence.  

Logo - http://photos.prnewswire.com/prnh/20151016/277630LOGO

SOURCE RDD Pharma

Related Links

http://www.rddpharma.com